

Aduhelm

Aduhelm is a medication designed to treat Alzheimer's disease. It is administered as an intravenous (IV) infusion over approximately one hour every four weeks and at least 21 days apart.

The accelerated approval of Biogen's Alzheimer's drug, Aduhelm, has been controversial, in part due to its significant side effects. Aduhelm was proven to significantly increase the incidence of cerebral edema (ARIA), cerebral microhemorrhages, headache, and mental disorientation.

The Aduhelm lawsuits claim that Alzheimer's patients who took Aduhelm were susceptible to a known side-effect of the drug (amyloid-related imaging abnormality-edema (ARIA-E) or swelling of the brain) that could result in death.

Criteria

- Any use of Aduhelm
- Diagnosis of ARIA-E or ARIA-H AND:
 - Death or
 - Seizure or
 - Stroke

